Can FDA Reinvent Inspections?

Agnes Shanley

Agnes Shanley is senior editor of Pharmaceutical Technology.

BioPharm International, BioPharm International-03-15-2021, Volume 2021 eBook, Issue 1
Pages: 4-5

A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?

Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.

Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.

Article details

BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 4–5

Citation

When referring to this article, please cite it as: A. Shanley, "Can FDA Reinvent Inspections,  BioPharm International Regulatory Sourcebook eBook (March 2021).